Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04966676
Title Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)
Acronym ATLAS
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications
Therapies
Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Princess Margaret Cancer Centre Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field